Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBTC Study 25: Tolerability of Higher Doses of Rifapentine
NCT00023426Phase 2Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Jul 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of rifapentine in Tuberculosis (TB) (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Proportion of patients who fail to complete therapy. Started Jul 1999; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00023426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023426.